Skip to content
Human-limitedParathyroid hormone analog for bone building

PTH (1-34) Teriparatide

Parathyroid hormone analog for severe osteoporosis anabolic therapy.

Overview

Binds to PTH1 receptors on osteoblasts, activating cAMP/PKA and Wnt signaling pathways for bone formation.

Proposed mechanism

Teriparatide is a recombinant human PTH fragment that stimulates osteoblasts via intermittent pulsatile exposure, increasing bone formation over resorption.

What the evidence supports

Human data exists but the trials are small, short-term, or not yet replicated.

Graded Human-limited

Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Teriparatide fracture reduction

    · DOI:10.1056/NEJMoa011930 · 2001

  2. [2]

    PTH anabolic therapy

    · DOI:10.1016/S8756-3282(02)00681-0 · 2002

  3. [3]

    Teriparatide fracture reduction (2001)

    · · 0

  4. [4]

    PTH anabolic therapy (2002)

    · · 0

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

AOD9604

Human-limited

Fat-targeting hGH fragment for metabolic support

AOD9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (amino acids 176–191), developed originally by Monash University as an anti-obesity drug. It mimics the lipolytic (fat-burning) effects of growth hormone without stimulating IGF-1 production or promoting cell proliferation. Research suggests it stimulates fat breakdown and inhibits fat formation, with a favorable safety profile compared to full-length hGH.

0 RCT · 0 human · 0 preclinical

fat-loss

Calcitonin (Salmon)

Animal

Salmon calcitonin for bone density

Calcium-regulating peptide for bone density & fracture prevention.

0 RCT · 0 human · 0 preclinical

Bone

FST 344

Animal

Myostatin blocker for serious muscle hypertrophy

FST 344 is a recombinant isoform of follistatin, a naturally occurring glycoprotein that binds and neutralizes myostatin and activin, two potent inhibitors of muscle growth. By suppressing these negative regulators, FST 344 promotes skeletal muscle hypertrophy, enhances recovery, and may support bone density. It has been investigated in gene therapy and preclinical contexts for muscular dystrophy and sarcopenia, though human clinical data remain very limited.

0 RCT · 0 human · 0 preclinical

growth